Corticosteroids reduce pacemaker implantation after alcohol septal ablation in oHCM patients

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Alcohol septal ablation (ASA) is a key treatment for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
• Complete atrioventricular block (CHB) is a known complication of ASA, often requiring permanent pacemaker (PPM) implantation.
• The role of post-procedural interventions in mitigating CHB complications remains an area of investigation.

Purpose of the Study:

• To evaluate the impact of post-procedural corticosteroid administration on the requirement for PPM implantation in oHCM patients who developed CHB following ASA.
• To identify potential therapeutic strategies to reduce the incidence of PPM implantation after ASA.

Main Methods:

• Retrospective analysis of 82 oHCM patients who developed complete atrioventricular (AV) block after ASA.
• Patients were divided into two groups: those receiving oral prednisolone (1 mg/kg for ≥3 days) and those not receiving corticosteroids.
• The primary endpoint was the need for PPM implantation during the index hospitalization.

Main Results:

• PPM implantation was required in 30.5% of patients (25 out of 82).
• The incidence of PPM implantation was significantly lower in the corticosteroid group (17.1%) compared to the no-corticosteroid group (43.9%; p=0.008).
• Corticosteroid use was independently associated with a reduced risk of PPM implantation (OR: 0.21, 95% CI: 0.07-0.66, p=0.007).

Conclusions:

• Post-procedural corticosteroid administration appears to significantly reduce the need for PPM implantation in oHCM patients experiencing CHB after ASA.
• These findings suggest corticosteroids as a potential adjunctive therapy to mitigate a major complication of ASA.
• Further prospective research is warranted to confirm these results and define optimal corticosteroid treatment protocols.